Analysts think NCNA stock price could increase by 2702%
Feb 18, 2025, 12:25 PM
-7.14%
What does NCNA do
NuCana PLC is a UK-based biopharmaceutical company focused on cancer treatments using ProTide technology, with candidates NUC-3373 and NUC-7738 currently in Phase I/II clinical trials. The company's pipeline also includes Acelari, a ProTide transformation of gemcitabine.
3 analysts think NCNA stock price will increase by 2702.20%. The current median analyst target is $25.50 compared to a current stock price of $0.91. The lowest analysts target is $25.25 and the highest analyst target is $26.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
